Digital Pathology & Imaging - software & AI news

Daily news on software, AI, and companies shaping digital pathology & imaging.

Showing 216 results
A flat illustration of a pathology slide with an AI brain overlay, symbolizing digital pathology.

May 26, 2026

Roche to Acquire PathAI to Expand Digital Pathology and AI Diagnostics

Roche has announced its intent to acquire PathAI for $750 million, aiming to enhance its digital pathology and AI diagnostic capabilities.The acquisition, which follows a partnership initiated in 2021, is designed to integrate PathAI’s advanced AI technologies and image management systems into Roche's laboratory workflows. This merger is expected to transition traditional manual processes to automated, AI-enhanced operations, thereby improving diagnostic efficiency and accuracy in pathology.By i
flat design of a radiology imaging device

May 26, 2026

Jardine Matheson Expands Into Healthcare AI With I-MED Buy

Jardine Matheson is making a significant foray into healthcare AI with its acquisition of I-MED Radiology Network, a move that signals a strategic pivot for the traditionally diversified conglomerate.Valued at A$3.4 billion (US$2.4 billion), this acquisition grants Jardine access to one of Australia’s largest diagnostic imaging providers, positioning the company to leverage the burgeoning field of artificial intelligence in healthcare. Notably, the deal also secures a minority stake in Harrison.
A minimalist illustration of a microscope and a cell sample in flat design.

May 25, 2026

Roche Enters Into a Definitive Merger Agreement to Acquire PathAI to Transform AI-Driven Diagnostics

Roche has entered a definitive merger agreement to acquire PathAI, aiming to enhance AI-driven diagnostics in pathology.The acquisition of PathAI, a leader in digital pathology and AI technology, is set to bolster Roche's existing capabilities in companion diagnostics. This move follows a successful partnership initiated in 2021, which has now evolved to include the development of AI-enabled diagnostic algorithms. The deal is expected to close in the latter half of the year, after which PathAI w
A minimalist representation of a smart otoscope for pediatric healthcare.

May 24, 2026

EarSmartAI: Pre-Seed Investment To Advance AI-Powered Pediatric Ear Infection Diagnostics

EarSmartAI has secured a $250,000 pre-seed investment from Boomerang Ventures to enhance its AI-driven diagnostic platform for pediatric ear infections. This funding comes as the company aims to meet the rising demand for efficient pediatric healthcare solutions.Located in Indianapolis, EarSmartAI is developing a connected care platform that allows parents to evaluate potential ear infections at home. Utilizing a smart otoscope, proprietary AI algorithms, and a mobile app, the platform targets t
Flat design of a medical imaging device

May 24, 2026

Siemens Healthineers Wins FDA Nod for AI Imaging Suite as Diagnostics Crisis and Spin-Off Plan Domin

Siemens Healthineers has received FDA approvals for its AI imaging technology, but faces challenges in its diagnostics division.Siemens Healthineers recently achieved six regulatory approvals for its Artis interventional imaging portfolio, marking a significant advancement for its Optiq AI imaging chain, which enhances image quality using deep learning. However, this positive development contrasts sharply with the ongoing struggles in its diagnostics unit, which experienced a 6.5% revenue declin
A tissue sample on a microscope slide in a lab setting

May 21, 2026

Roche to Acquire PathAI to Drive Diagnostics

Roche has announced its intent to acquire PathAI, a leader in digital pathology and AI diagnostics, in a move aimed at enhancing its capabilities in precision medicine.The acquisition, which follows a successful partnership initiated in 2021, will allow Roche to integrate PathAI's advanced digital pathology tools into its existing oncology diagnostic platforms. This integration is expected to streamline diagnostic workflows by transforming traditional manual processes into automated, AI-driven o
A prostate biopsy needle and sample in a clinical setting.

May 21, 2026

Prostate Cancer Diagnostics Market to Reach US$ 14.83 Billion by 2034 Amid Rising Cancer Awareness

The prostate cancer diagnostics market is on a robust growth trajectory, anticipated to expand from US$ 8.12 billion in 2025 to US$ 14.83 billion by 2034, reflecting a compound annual growth rate (CAGR) of 6.92% from 2026 to 2034. This growth is largely driven by heightened awareness of prostate cancer, government-supported screening initiatives, and advancements in diagnostic technologies.The increasing incidence of prostate cancer, particularly among men over 50, is a significant factor fuelin
A stethoscope and brain silhouette representing AI in healthcare

May 21, 2026

Guangzhou Kingmed Diagnostics Group Delivers Keynote Speech on "Digital and Intelligent Diagnostics Empowering a Global Community of Health for All" at the Global South Media and Think Tank Forum

Guangzhou Kingmed Diagnostics Group recently highlighted the role of digital intelligence in promoting healthcare equality during a keynote address at the Global South Media and Think Tank Forum in Cairo.Liang Xiaodan, Vice President of Kingmed, discussed the company's innovative approach to addressing disparities in medical resource distribution and diagnostic capabilities through an AI-driven "Medical Diagnostics + AI" model. This initiative aims to provide accessible, high-quality healthcare,
A blood sample in a test tube rack in a dimly lit lab setting.

May 20, 2026

Noul wins Korean funding to push AI blood analyzer toward US FDA, Europe

Noul has recently secured funding from the Korean government to propel its AI-driven blood analysis platform, miLab BCM, towards achieving regulatory approvals in the U.S. and Europe.The funding, amounting to 2.2 billion won (approximately $1.6 million), is part of a multi-ministerial initiative to support advanced medical device R&D. This investment aims to facilitate multinational pivotal studies that will generate essential clinical performance data for regulatory clearance and commercializat
A minimalist illustration of a heart and echocardiogram wave pattern.

May 19, 2026

Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

Ventripoint Diagnostics is making strides in the AI cardiac imaging sector, capitalizing on a rapidly evolving procurement landscape.The landscape for medical artificial intelligence in cardiology is shifting dramatically, with hospitals increasingly seeking not just clinical accuracy but also economic justification before deploying new technologies. This trend has significant implications for companies like Ventripoint Diagnostics Ltd., which is leveraging its proprietary Knowledge Based Recons
Tissue sample on a lab bench with digital pathology equipment in the background.

May 18, 2026

Revolutionizing Cancer Care: AstraZeneca and Roche's Pioneering AI Partnership

AstraZeneca and Roche Diagnostics are embarking on a transformative three-year partnership aimed at enhancing cancer care in Asia through advanced AI-driven digital pathology.This collaboration marks a significant milestone as it introduces AI-powered digital pathology across nine Asian markets, focusing on education and training to foster the adoption of these technologies. Given that Asia accounts for nearly half of global breast cancer cases and over 60% of new lung cancer diagnoses, the need
A minimalist representation of a biomarker test strip with a sample drop.

May 18, 2026

AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer

AstraZeneca and Roche Diagnostics Asia Pacific have initiated a three-year partnership aimed at enhancing digital pathology capabilities and cancer care in nine Asian markets. This collaboration seeks to promote the use of AI-driven digital and computational pathology, particularly focusing on improving biomarker testing for breast and lung cancers.With nearly half of breast cancer cases and over 60% of new lung cancer diagnoses occurring in Asia, precise biomarker testing is increasingly vital